Condition
Severe Insulin Resistance
Total Trials
2
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Hrpqct Scan
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
1Total
Phase 2 (1)
Trial Status
Active Not Recruiting1
Recruiting1
Clinical Trials (2)
Research Network
Common Treatments
- Hrpqct Scan1
- Metreleptin1
Active Sponsors
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2
Top Investigators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Related Conditions
- Diabetes Mellitus1